RegeneRx files $60 million stock, warrants shelf

New York, June 16 - RegeneRx Biopharmaceuticals, Inc. filed a $60 million shelf registration for common stock and warrants with the Securities and Exchange Commission.

The stock and warrants may be sold separately or together, according to the S-3 filing.

The Bethesda, Md., biopharmaceutical company developing Thymosin beta 4 for the treatment of acute and chronic wounds and for the treatment of a variety of human diseases involving tissue and organ repair will use proceeds for additional clinical trials for myocardial infarctions, ophthalmic indications and general corporate purposes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.